Compare Commvault Systems Inc (CVLT) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Commvault Systems Inc vs DexCom, Inc. — how do they compare? Commvault Systems Inc trades at $151.12 (market cap $6.25B), while DexCom, Inc. trades at $83.71 (market cap $31.86B). The key difference: DexCom, Inc. is far larger — about 5.1× Commvault Systems Inc's market cap, and Commvault Systems Inc is more actively traded (632,727 versus 3,607,070). Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and DexCom, Inc. for 62 Days on average.
| CVLT | DXCM | |
|---|---|---|
Market Cap | $6.25B | $31.86B |
Volume | 632,727 | 3,607,070 |
Sector | Technology | Health |
52-Week High | $176.52 | $92.34 |
52-Week Low | $75.18 | $54.84 |
Typical Hold Time | 17 Days | 62 Days |
Enterprise Value | $6.24B | $31.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $150.74, up 0.31% with strong bullish technical momentum. The stock shows robust earnings performance, beating estimates for three consecutive quarters, with Q3 2026 results pending. Recent business developments include AWS Data Competency achievement and expanded FedRAMP authorization, positioning the company for growth in AI-driven resilience markets.
The outlook remains positive with 54.5% analyst buy ratings and a $156.55 consensus target, though high valuation multiples and declining profit margins warrant caution. Key risks include competitive pressures in cybersecurity and execution challenges in maintaining growth momentum amid expanding AI capabilities.
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
